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ABSTRACT 
Introduction: There is an increase in the use of nanoparticles (NPs) throughout the world. 
Gold nanoparticles (AuNPs) are commonly used NPs in the field of biomedicine. NPs bigger 
than 8 nm are excreted via the hepatobiliary system. Bile acids (BAs) are regarded as the main 
components of bile. If there is a decreased or increased secretion of BAs, the composition of 
microbiota in the gut can change. Under normal physiological condition BAs fluctuates daily 
without causing any harm. Nevertheless, it is the long-term changes in bile acid secretion that 
can affect microbiota in the gut. If there is an increased excretion of AuNPs via hepatobiliary 
pathway it can alter bile formation. 
Aim: The aim of this study was to investigate whether the hepatobiliary excretion of AuNPs 
will alter the bile formation two weeks after intravenous administration of 14 nm AuNPs to 
Wistar rats. 
Method: Rat liver samples of two previous experiments were used to investigate bile 
formation. The rats had been injected intravenously with a single dose of citrate capped and 
functionalised AuNPs. These rats were killed 14 days later. Small pieces  of liver were stored 
in RNAlater. The mRNA of different enzymes and transporters in the hepatobiliary system 
were quantified in these samples and compared with suitable control. As a reference the mRNA 
of the same enzymes and transporters were extracted and quantified in rat liver that were killed 
one day after injection with one of the abovementioned functionalised AuNPs. 
Results and Conclusion: The study shows down-regulation of genes responsible for 
conjugation of BAs whereas the rate-limiting enzymes were not significantly changed. This 
was the first study to investigate the formation of bile in relation to the use of AuNPs. The 
effect and consequences of AuNPs on the hepatobiliary system need further investigation. 
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     CHAPTER ONE 
INTRODUCTION 
The introduction of nanotechnology is anticipated to offer a huge improvement in medicine 
through discoveries of targeted vehicles for imaging, diagnostics and therapy (Wu et al., 2016). 
Wang (2013) defines nanotechnology as the study of manipulating matter on an atomic and 
molecular scale. Application of nanotechnology offers new and proficient technology such as 
the use of nanoparticles that allow molecular specific labelling and therapy. There has been a 
need to develop nanoparticles (NPs) over the past years mainly to deliver drugs effectively 
(Sonavane et al., 2008). 
1.1 The application of gold nanoparticles 
Applicability of gold nanoparticles (AuNPs) in a biological and medical field is wide. To be 
more specific, AuNPs have been used in areas like clinical chemistry, biosensors, hygiene 
detection of cancer cells, genomics and more. It can be said that use of AuNPs can be seen in 
almost every medical application. These particles are widely used in disease prevention, 
diagnosis and therapy (Li et al., 2014). In this context, it can be mentioned that the application 
of AuNPs depends on its unique chemical and physical properties. The optical properties of 
AuNPs can be determined through plasmon resonance. This, in turn, has been associated with 
conduction electrons that can be localised across visible and infrared regions. 
Singh et al. (2015) indicates that the preference of NPs in the imaging and treatment of cancer 
lies in their properties. NPs have large surface area to volume ratio, this property is particularly 
important as it allows the particles to be held in suspension, include targeting moieties, 
facilitate drug encapsulation and high loading capacity as well as allow widespread surface 
absorption (De Visschere et al., 2010). 
AuNPs have attracted many researchers due to their unique physical and chemical properties 
(Elahi et al., 2018). These are said to carry some unique properties which make it more reliable 
or most likely to be applied in diagnosis and treatment. There are a number or subtypes of 
AuNPs, these various forms are distinguished based on their size, shape and physical properties 
(Dickson et al., 2010). Based on physical properties, the following types of AuNPs exist; 
colloidal gold, gold nanospheres, gold nanorods, gold nanoshells and gold nanocages (Wang, 
2013). As briefly mentioned, the preference of AuNPs is based on their extraordinary ability 
to target and image body cells at the cellular and molecular level. The specific qualities include; 
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their ability to recognize cancer cells, their size and optical properties determined by the size 
of AuNPs and lastly AuNPs are known to be biocompatible (Wang and Wang, 2014). 
Metal NPs have been developed for essential medical applications due to their intrinsic 
properties including anti-cancer and anti-inflammatory activities and plasmonic properties 
(Cucci et al., 2018). Optical detection of cancer has been greatly improved by the newly 
discovered application of AuNPs. In addition, their negligible toxicity to cells makes them 
suitable for cancer targeted therapy (Singh et al., 2015). 
The overall goals for the use of AuNPs in biomedicine is to increase precision and reduce the 
cost of treatment and eventually reduce the number of deaths resulting from various diseases 
such as cancer (Kumar and Paulsi, 2013). Application of nanotechnology offers new and 
proficient technology such as the use of NPs that allow molecular specific labelling and therapy 
(Wang, 2013). Research on AuNPs which focused on light emission and scattering properties 
has informed its use in locating tumours and enabling targeted delivery at the tumour site 
(Viswanath et al., 2016). The introduction of AuNPs with an excellent biodegradable and 
biocompatible properties in the field of oncology is a breakthrough for both detection and 
therapy (Revia and Zhang, 2016). AuNPs have an important medical application such as 
biological imaging and therapy due to their stability, biological compatibility and easier 
synthetic methods (Gamal-Eldeen et al., 2017). 
Incorporating metal NPs in animals and human studies has positively revolutionized the field 
of biomedicine. AuNPs with its unique properties such as a large surface area, low inherent 
toxicity and easy functionalization are the main reasons why AuNPs have developed a huge 
attraction in nanotechnology (Bodelón et al., 2017). Nevertheless, it has been found that when 
AuNPs enter the biological systems they usually accumulate in the liver and spleen and these 
accumulations may change certain genes and may damage the liver as a long-term effect. 
Therefore, it is of great interest to develop AuNPs that can be broken down and cleared easily 
to reduce the possible detrimental effects (Zhang et al., 2012). 
Although there is continuous use of nano-based products, less studies are conducted on the 
ultimate elimination mechanism of AuNPs. Furthermore, the use of NPs in medicine is likely 
to initiate controversy because their safety and elimination patterns are not clearly understood 
(Zhang et al., 2016). Due to these safety concerns, it is therefore essential to understand the 
detailed ultimate elimination pattern and life cycle of these NPs in testing and clinical trials. 
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The methods of reducing toxicity such as metabolism and excretion, and elimination of AuNPs 
are of great interest clinically (Jenkins et al., 2013). 
According to Lopez-Chaves et al. (2018) the ultimate fate of AuNPs that are injected 
intravenously are distributed into different body organs depending on their size. Their study 
further pointed out that smaller AuNPs distributes throughout the body tissues within 24 hours 
after injection whereas bigger sized AuNPs accumulates in the liver. 
AuNPs bigger than 8nm are excreted via the hepatobiliary system and therefore accumulation 
in the liver 24 hours after injection should be regarded as a normal or healthy. 
Bile consists of 65% of bile acids (BAs) (Esteller, 2008). It has been established that elevated 
secondary BAs levels are associated with colonic carcinomas (Ding et al., 2015). A change in 
bile acids secretion can also change the composition of the microbiota, which may have other 
indirect effects (Marra and Svegliati-Baroni, 2018). There is an important interplay between 
host, microbiota population and BAs metabolism (Mandal, 2018). There are fluctuations on 
BAs secretion on a daily basis, which the body is used to. However it is a rather longer term 
change in BAs secretion that can affect the microbiota. Increased AuNPs clearance via the 
hepatobiliary system can therefore affect the BAs secretion. No publications could be found on 
the effect of AuNPs on the biliary system two weeks or later after injection. It is the aim to 
synthesize NPs with optimal clearance characteristics and minimum interference with 
physiological procesess (Longmire et al., 2008). 
Therefore, there is a need to investigate the long-term effect of bile synthesis during the 
excretion when AuNPs are removed from the liver via the hepatobiliary system into faeces. 
1.2 RESEACH AIM AND OBJECTIVES 
1.2.1 The aim of the study is to investigate whether the hepatobiliary excretion of AuNPs will 
alter the bile formation two weeks after intravenous administration of 14 nm AuNPs to Wistar 
rats. 
According to Kreyling et al. (2015) it is difficult to measure bile flow in rats, especially because 
they do not have a gall bladder. For this research liver samples of rats, which had been injected 
with peptide conjugated AuNPs, were used. 
1.2.2 Objectives 
➢ Extraction of messenger ribonucleic acid (mRNA) 
➢ Quantification of mRNA 
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➢ Complementary deoxyribonucleic acid (cDNA) synthesis 
➢ Quantification of cDNA 
➢ Quantitative polymerase chain reaction (qPCR) run and analysis 
➢ Analysis and interpretation and of statistics 
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     CHAPTER TWO 
     LITERATURE REVIEW 
There are several advantages of AuNPs for nanomedicine, however there is still a paucity to 
become over excited about these possibilities, because the excretion of these particles has not 
been fully described and the fate of the NPs after entering the body is still unclear. It has been 
described that when the excretion of NPs was delayed, it caused toxicity and tissue damage 
(Seo et al., 2015). 
2.1 Excretion of AuNPs 
AuNPs are essentially considered to be bio-inert (Jia et al., 2017). Another advantage of AuNPs 
is that the surface charge can easily be modified (Longmire et al., 2008) and therefore the 
functionality of the AuNPs can easily be changed. 
2.2 General behaviour of AuNPs in vivo 
Following intravenous administration NPs encounter different components like cells, plasma 
proteins and different ions. Depending on the characteristics of the NPs, like size and charge, 
the NPs’ surface can be modified by serum proteins. This can change the effective size of the 
particle resulting in a particle diameter (referred to as the in vivo hydrodynamic diameter), 
which may be considerably larger than the in vitro diameter. The hydrodynamic diameter of 
the NPs can affect the blood clearance (Longmire et al., 2008). Attaching polyethylene glycols 
(PEG) to the NPs, make them more stable to be introduced to body fluids. 
According to the study the biodistribution of AuNPs into various organs depends on their 
surface charge. It has been found that non-charged and negatively charged NPs accumulates 
more in the kidney whereas the positively charged AuNPs accumulates more in the liver. Once 
AuNPs arrive in the liver, hepato-biliary route removes these NPs into the smaller intestines 
via the biliary duct pathway allows for clearance through the biliary duct into the duodenum 
(Hirn et al., 2011). 
2.3 The role of size in excretion 
NPs are ten thousand times less than the size of human cells. There is an avalanche of 
information showing that NPs with a diameter of 20 nm or less are easily removed from the 
biological systems through hepatobiliary system and kidneys (Zhang et al., 2009). 
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2.4 Nanoparticle clearance 
NPs can be cleared from the body primarily in two ways namely; the renal (via urine) and 
hepatobiliary system (via feces). Alternatively, the nanoparticles can be phagocytised by 
macrophages and stored within vesicles in the macrophages for an extended period (see figures 
1 and 2 below). 
 
Figure 1: The schematic representation indicating the clearance of nano-based particles by 
various pathways namely; mononuclear phagocyte system, kidneys and hepatobiliary system. 
Arrows that are in solid form show the most probable interaction whereas dashed arrows 
indicate a possible communication. If the target tissue (disease tissue) is not present 
nanoparticles with size of 6nm or less are excreted in urine by the renal pathway whereas 
nanoparticles that are more than 6nm are cleared primarily by the hepatobiliary system. Non-
degradable NPs are kept for months to years by the mononuclear phagocyte system, and these 
NPs may later return to the bloodstream and be removed by the hepatobiliary system (Zhang 
et al., 2016).
7 
 
2.4.1 Renal Clearance 
According to Papasani et al. (2012) the clearance of AuNPs by the renal pathway is size-
dependent. The study suggests that particles with a size range of 5-10 nm are cleared effectively 
by the kidneys. The kidneys have the machinery in place that includes a rich blood supply 
designed to cleanse the blood. The renal arteries deliver a quarter of cardiac output to the 
kidneys. Small AuNP (5-10nm) circulating in the blood will filtrate via the pores in the 
glomerulus. 
 
Figure 2: Renal handling of nanoparticles (Longmire et al., 2008). 
The filtrate which flows through proximal tubule, the loop of Henle and distal tubule, will not 
be reabsorbed into the interstitial fluid and circulation via vasa recta, unless there are specific 
transporters for the AuNPs in the nephron (see figure 3 below) (Tortora and Papasani, 2017). 
AuNPs (which do not have specific transporter) will therefore move with the filtrate to the 
bladder and excreted as urine. Although the renal system is a desirable route of excretion for 
NPs, the walls of glomerular capillary can only allow through NPs with a diameter of 8 nm or 
less because of the filtration-size threshold. Therefore, the hepatobiliary is referred to as a 
primary excretion pathway for NPs larger than 8 nm. During excretion the liver cells removes 
NPs into bile prior to elimination in feces (Jenkins et al., 2013). 
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Figure 3: The image showing sections of a nephron (Kardasz, 2009). 
2.4.2 Hepatobiliary clearance of gold nanoparticles 
The hepatobiliary system is the initial route of particle excretion which have not been removed 
by renal clearance (Daraee et al., 2016). This means that the liver acts as an important route for 
eliminating foreign particles and substances. Hepatocytes contribute to clearance by the liver 
via enzymatic breakdown and endocytosis of foreign particles (Kolosnjaj-Tabi et al., 2015). 
The hepatobiliary system uses the structural advantage of ciliated Kupffer cells (main 
phagocytes of the liver) to remove unwanted materials. Kupffer cells, engulf foreign material 
(endocytosis), process them (enzymatic activity) and excrete unwanted particles into the bile 
or store particles in the Kupfer cells (Longmire et al., 2008). 
Seo et al. (2015) used transmission electron microscopy (TEM) to understand the mechanism 
of hepatobiliary excretion. The ex vivo biodistribution results showed the hepatic clearance rate 
to be above 80% within a period of 72 hours from the moment the liver took the injected 
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AuNPs. Under normal physiological conditions the nanoparticles with a size bigger than the 
pores of the glomerulus are kept in the spleen or liver after injection. Inside the liver, the 
injected AuNPs are engulfed by either hepatocytes or Kupffer cells. NPs that goes into the 
hepatocytes are excreted via the hepatobiliary pathway. Hepatocytes engulf nanoparticles that 
are less than 100 nm in size. In accordance with the optimization it was clear that NPs with a 
size 34.4 nm are easily excreted via hepatobiliary system as compared to 50 nm that was 
initially known as optimal. However, Longmire et al. (2008) suggested that the hepatobiliary 
system was the primary site for clearance of NPs from 10-250 nm. The study further explained 
a significant variation that exists between Kupffer cells and hepatocytes. Hepatocytes which 
are located within the hepatobiliary route are responsible for processing particles and excrete 
them into bile whereas Kupffer cells forms part of the reticuloendothelial system (RES) that 
removes degraded particles. In the current study different AuNP of about 14 nm was used and 
therefore the emphasis of this study is to determine whether the hepatobiliary system was 
increased in activity after intravenous injection of AuNP. 
2.5 Role of bile in excretion of gold nanoparticles 
According to Eshraghi et al. (2015), bile formation also increases due to excretion that happens 
to be a positive effect on the bodies of experimental animals like rats. Though it can also be 
mentioned that an excessive level of bile formation can be harmful to any animal especially 
small animals like rats. 
2.5.1 Concept of bile formation 
The bile is described as advanced fluid constituting of electrolytes, water, bile acids, bilirubin, 
cholesterol and phospholipids. These components of bile flows within the biliary tract from the 
gallbladder into the small intestines (Azum et al., 2019). 
Bile refers to a complex kind of aqueous secretion which is generated by hepatocytes. This 
secretion can be modified or changed due to an absorptive transport system inside the 
epithelium of bile duct. In this regard, it can be mentioned that bile has many important 
functions such as its role in excreting harmful substances from the body of living species. 
According to Tanimizu et al. (2016), the bile secretory unit includes a canalicular network that 
is closed by tight junctions adjacent to hepatocytes and Kupfer cells (See fig 8). 
The formation of bile is driven through concentration of BAs in canaliculi. According to the 
opinion of Eckstein et al. (2018), BAs are generated from cholesterol that is prior to excretion 
of hepatocytes. On the contrary, the flow of bile can be affected by various variables such as 
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nucleotidases and sub canalicular vesicles. Hepatocytes are responsible for the secretion of bile 
into the canaliculi. Bile canaliculi, known as small ducts, collects the secreted bile from the 
hepatocytes into the common hepatic ducts and deliver it to the common bile duct which joins 
with the cystic duct. Thereafter, bile travels into the duodenum to breakdown lipids and absorb 
fat soluble vitamins (Tortora and Derrickson, 2017). 
2.5.2 Composition and synthesis of bile 
BAs are considered as the main components of bile synthesized in the liver from cholesterol 
(Bustos et al., 2018). The word cholesterol is of Ancient Greek origin, chole meaning bile and 
stereos meaning solid which is followed by the suffix -ol for alcohol (Morzycki, 2014). In 
mammals, the synthesis and excretion of BAs play an essential role in the homeostasis of 
cholesterol (Martinot et al., 2017) (See figure 4 below). 
 
Figure 4: A chart indicating the perceptual spread of the components of bile (organic 
components). BP-biliary pigments, Chol-cholesterol, PL-phospholipids, BAs (Esteller, 2008). 
See the anatomical features responsible for the formation of bile in figures 5 and 6. 
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Figure 5: The images showing the anatomical Determinants of Bile Secretion. The upper 
image labelled (A). The lower image which forms the mesh of interconnecting shows the 
conduits of bile secretion. The connected hepatocytes show the position of bile canaliculus 
(b.c.), Disse’s space (d.s.), intercellular space (i.s.), and Kupffer cells (k.c.) and fenestrated 
endothelial lining cells. It is the tight junctions (t.j.) sealing the lumen of the b.c. which has 
microfilaments (m.f.) on its membrane. The cytoskeletal elements aid with the contraction of 
the canalicular during the peristaltic movement. Lastly, the sketch shows the rough 
endoplasmic reticulum (r.e.r.), nucleus (n.) and golgi apparatus (g.a) (Boyer, 2013). 
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Figure 6: A TEM image indicating the Replica of bile canaliculus (BC). The intercellular space 
lined by the lateral membrane (LM) and bile are the only two factors serving as anatomical 
barrier (Boyer, 2013). 
2.6 Bile formation in rats 
One of the key functions of the liver is the formation of bile because it serves as an important 
excretory route of xenobiotics and endobiotics (Cermanova et al., 2015). Basolateral and apical 
membranes of liver cells play an essential role as coordinating transporter proteins that 
mediates the secretion of bile. Furthermore, basolateral and apical membranes are known to 
excrete glutathione and BAs which aid in the production of osmotic gradient, which ultimately 
helps to release water into the biliary duct (Prasnicka et al., 2017). Movement of solute and 
water happen via cell membrane across complex of an intercellular junction. According to 
Karpen and Dawson (2015), a permeability of pathways in animal body can be increased due.  
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 to osmotic gradients. According to the above-mentioned scenario, it can be said that though 
below formation is an important factor in enterohepatic circulation in rats, but an excessive 
amount of bile flow can be harmful to them. 
2.7 Osmotic theory of bile formation 
Osmotic theory regarding bile formation was articulated by the Swedish physiologist Sperber 
in 1959 in the review titled “secretion of organic anions in the formation of urine and bile”. 
This theory is very relevant in explaining process of bile formation. According to this scientific 
experimentation on anaesthetized chicken, intravenous injection of bile acids and cholephiles, 
in the laboratory animals mentioned above, affects bile flow stimulation and bile concentration. 
According to Schaap et al. (2014), Sperber has been influenced by Pappenheimer who claimed 
that water can flow through semipermeable membrane as an outcome of origination of osmotic 
gradients. On the contrary, osmotic theory opines that osmotic filtration stimulates diffusion of 
water passively. In opinion of Lv et al. (2016) osmotic filtration is an important factor in 
formation of bile in animal body. 
On the other hand, bile acid’s effect of osmotic gradients differs according to proportion of tri, 
mono and dihydroxy bile fluids, acids and their concentration. This effect has been termed as 
a basis of physiological effects on animal body. 
2.8 BAs synthesis and conjugation 
A series of enzymatic process using 17 enzymes that are found in several intra-cellular 
compartments of liver cells such as cytosol, microsomes, mitochondria and peroxysomes are 
responsible for the synthesis of primary bile acids. These multi-enzymatic reactions results in 
the size reduction of side chain, modifications of the cholesterol ring structure and oxidation 
of the side chain (Martinot et al., 2017). BAs are considered as the main components of bile 
synthesized in the liver from cholesterol. Firstly, the primary BAs (chenodeoxycholic acid 
(CDCA) and cholic acid (CA)) undergo conjugation by binding to either taurine or glycine in 
the liver prior to storage in gallbladder (in the human and some mammals). After a meal bile 
is excreted into the small intestines. These BAs primarily serves as an emulsifying agent that 
breaks down fat-soluble vitamins and fats for efficient absorption (Bustos et al., 2018). 
In the liver BAs are synthesized from cholesterol, goes into bile canaliculi by multidrug 
resistant-associated protein 2 (MRP2) and bile salt export pump (BSEP). Bile acid-CoA: amino 
acid N-acyltransferase (BAAT) is responsible for the conjugation of BAs. During the 
stimulation of gallbladder by cholecystokinin (CCK), BAs are released into duodenum. In the 
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small intestine microbiota deconjugate BAs to form LCA and DCA. LCA is insoluble and 
excreted into feces but DCA can be reabsorbed into the portal vein and recycled. BAs in turn 
act on the Farnesoid X receptor (FXR) to downregulate CYP8B1 and 7α-hydroxylase 
(CYP7A1) by inducing the short heterodimer partner (SHP) (Chow et al., 2017). The 
impairment of SHP will result in a decreased inhibition CYP8B1 and CYP7A1 and thus 
causing increased synthesis of BAs (Kerr et al., 2002). 
An active uptake mechanism ensures that 95% BAs are completely absorbed when arriving at 
the end of ileum, and thus preventing loss in feces to a range of about 0.2-0.6 g/day. In the 
distal small intestine and colon, the primary BAs, CA and CDCA, undergo deconjugation and 
dehydroxylation by resident bacteria, resulting in the formation of secondary BAs (i.e., These 
secondary BAs can be reabsorbed passively and constitute a portion of the total BA pool that 
cycles in the enterohepatic circulation. The microbiota in the distal small intestines and colon 
deconjugate and dehydrolyse CDCA and CA to form deoxycholic acid (DCA) and lithocholic 
acid (LCA). The DCA and LCA are secondary BAs which can be reabsorbed passively and 
form part of the enterohepatic circulation (Arab et al., 2017). It is in the ileum where they are 
absorbed and return through portal vein to the liver in what is referred to as enterohepatic 
circulation (Wang et al., 2018). 
Figure 7 below shows the enterohepatic circulation and the enzymes involved in the synthesis 
of bile acids.  
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Figure 7: The schematic representation of enterohepatic circulation of BAs. Red arrows: 
downregulation. Green arrows: Upregulation. Broken arrows: other pathways not forming part 
of enterohepatic circulation (Chow et al., 2017). 
2.9 Uptake of FXR and feedback mechanism on liver and bile production 
In opinion of Chatterjee et al. (2014), liver can be termed as a commonly used route for toxins 
and chemicals to be eliminated via faeces from body. The role of bile in excretion of injected 
AuNPs is that the AuNPs which accumulate in liver, are excreted through the bile. The 
significance lies in the fact that, to our knowledge, excretion of these particles (14 nm AuNPs) 
can be done only through hepatobiliary pathway.  
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FXR belongs to the nuclear receptor (NR) family in the subclass of metabolic receptors and it 
acts as a NR for BAs. It is found in several tissues such as kidneys, fat tissue, liver, intestines. 
The level of BAs in enterohepatic circulation are primarily regulated by FXR. An enzyme 
known as 7α-hydroxylase is responsible for the synthesis of BAs prior to conjugation. 
Immediately after conjugation of BAs with taurine and glycine, BAs are secreted into the 
canalicular lumen via two ABC transporters called MRP2 and BSEP. Prior to excretion into 
the small intestines they are stored in the gallbladder (Ding et al., 2015). See in figure 8 (below) 
the movement of bile and how it excretes substances via the hepatobiliary pathway into the 
small intestines. FXR negative feedback inhibits the formation of bile (Gonzalez et al., 2016). 
 
Figure 8: The image showing the movement of bile into the small intestines (adapted from 
Zhang et al., 2016). 
In this study the mRNA of different enzymes on the hepatobiliary pathway (CYP7A1, 
CYP27A1, CYP8A1, BAAT and FXR as well as the transporter BSEP were quantified to 
determine whether the injection of 14 nm AuNP affect the synthesis, secretion of feedback of 
the biliary system. 
2.10 Method to determine changes in enzymes and transporters. 
Quantitative polymerase chain reaction is an important biomedical tool that is used to measure 
and give information about messenger ribonucleic acid (mRNA) (Karlsson et al., 2016). There 
is an assumption that is mRNA is translated into the relevant protein synthesis, therefore a  
correlation between mRNA and the protein exist (Greenbaum et al., 2003). From the 
abovementioned correlation it is reasonable to validate the mRNA data by measuring protein. 
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However, this was not possible in this study due to a limited time frame as this is a coursework 
by research. 
2.10.1 Reverse-Transcription quantitative polymerase chain reaction (RT-qPCR) 
RT-qPCR was used in this study to quantify mRNA of the named enzymes and transporter in 
the hepatobiliary system. The process involves RNA extraction, quantification of RNA, 
synthesis of cDNA, qPCR run and analysis of qPCR run data. In the study experimental design 
for mRNA analysis was MIQE compliant (MIQE-minimum information for publication of 
quantitative real-time PCR experiments).  
MIQE is primarily aimed at improving the transparency and ultimately the outcome of assays 
that were published by pointing out the important minimum requirements. It is therefore 
essential to note that minimum does not refer to ideal (Bustin et al., 2011). There is a need to 
report details of every aspect of qPCR assay, including parameters of both post- and pre-qPCR 
assay (Abdel Nour et al., 2014). MIQE outlines best experimental practices for gene expression 
experiments enabling researchers to get quality data (Taylor and Mrkusich, 2014).
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CHAPTER THREE 
     METHODOLOGY 
3.1 Required materials and reagents 
➢ Next advance bullet blender storm 24 (Biocombiotech) for tissue homogenization and 
disruption 
➢ RNA extraction kit (Bio-Rad, Catalogue number 7326870, USA) 
➢ Chloroform 
➢ 70 % ethanol 
➢ Nuclease-free water 
➢ 1.5 ml and 2 ml RNase-free tubes 
➢ Nanodrop 2000c spectrophotometer (Thermo Scientific) 
3.2 Ethical considerations 
Clearance letters were issued by Nelson Mandela Research Ethics Committee to conduct the 
study on animals prior to the commencement of the study. The liver samples used in this study 
came from animals used in previous studies (Adewale, 2018 and Cairncross, 2015) with animal 
ethics clearance numbers A15-SCI-BCM-002 and A13-SCI-ZOO-013 respectively. The 
Wistar rats were handled and maintained with care in compliance with the South African 
National Standards (SANS). See appendix A for the details. 
3.3 Experimental Design 
Gold nanoparticles were synthesized by chemical reduction of chloroauric acid by trisodium 
citrate, which acts both as reducing agent and as capping agent. To distinguish between effect 
of gold and effect of functionalised groups, gold particles at different stages of synthesis were 
injected. 
Dr Adewale Olusola’s study involved 36 male Wistar rats aged 12 weeks. Wistar rats were 
obtained from North West University. They were housed according to ethical standards, 
receiving ad lib food and water in a light and temperature-controlled animal room. The rats 
were injected intravenously with citrate capped AuNPs (citrate-AuNPs), polyethylene glycol 
(PEG) conjugated AuNPs (PEG-AuNPs) and AuNPs functionalised with different peptides 
namely; p.L (p.L-AuNPs), p.14 (p.14-AuNPs) and p.C (p.C-AuNPs) respectively. Peptide-
AuNP were synthesized according to the method that is currently used in the lab. Using the 
Turkevich method, 14 nm spherical peptide conjugated gold nanoparticles (p-AuNP) were 
synthesized and characterized as described by (Sosibo et al., 2015). Table 1 below shows each 
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group and its treatment. These rats were killed 14 days after injection. Two groups of male rats, 
untreated (named HL) and treated p.C-AuNPs. These rats were used previously for the study 
of Ms Lynn C. Cairncross, 2015. They were killed after 1 day and were included to get an idea 
whether the measured enzymes and transporters are affected after one day. 
Table 1: Different groups and AuNPs used for injections 
Groups Treatment Days after injection killed 
1 Control 1 Day 
2 p.C-AuNPs 1 Day 
3 Control 14 Days 
4 Citrate-AuNPs 14 Days 
5 PEG-AuNPs 14 Days 
6 p.L-AuNPs 14 Days 
7 p.14-AuNPs 14 Days 
8 p.C-AuNPs 14 Days 
 
3.4 Total Ribonucleic acid extraction using PureZOL 
Liver samples were stored in 1 mL RNAlater at -20 °C. The ribonucleic acid (RNA) extraction 
kit (Bio-Rad, cat. #7326870) for fatty and fibrous tissue was used for total RNA extraction. 
Frozen liver tissues of approximately 100 mg were transferred int a 750 mL centrifugation 
tubes containing 1 mL of pureZOL and 0.5 mm Zirconium oxide beads (Ribonuclease 
(RNase)/Deoxyribonuclease (DNase) free, next advance). The samples were not weighed prior 
to homogenization to avoid thawing and contamination. All samples were completely 
immersed in pureZOL. The samples (liver tissues) were then homogenized by a next advance 
bullet blender storm 24 (Biocombiotech) for 5-15 minutes to homogenize the samples 
completely. The lysate was incubated at room temperature after homogenization for 5 minutes 
allowing the nucleoprotein complexes to dissociate fully. Immediately after incubation of the 
lysate, 0.2 mL of chloroform was added and vigorous shaking of the tubes by a hand. The 
samples were further mixed periodically at room temperature for 5 minutes. The mixture was 
centrifuged for 15 minutes at 12000 × g at a temperature of 4 °C. 
The following solution was prepared to remove the contaminating deoxyribonucleic acid 
(DNA). Firstly, DNase 1 enzyme was prepared by reconstituting DNase. This was done by 
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adding 250 µL of 10 mM Tris-HCl of pH 7.5 to the lyophilized powder. To process each 
column, 75 µL of DNase dilution solution was mixed with 5 µL of reconstituted DNase I. 
Immediately after the centrifugation, the aqueous (colourless) phase was transferred into a 2 
mL tube. This was followed by adding an equal volume of approximately 600 µL of 70 % 
ethanol and pipetted the mixture up and down to mix completely. RNA binding column were 
inserted into a capless tube for washing. To each column 700 µL of the sample was added and 
centrifuged at 12000 × g for 60 seconds. This step of adding the RNA sample was repeated for 
the remainder of the sample. Low stringency wash solution (700 µL) was added to the RNA 
binding column and centrifuged at 12000 × g for 30 seconds. 
To successfully remove contaminating DNA from the RNA sample, 80 µL of DNase I was 
added at the middle of the membrane stack. This was followed by a 15 minutes incubation 
period to allow the DNase digest. A high stringency wash solution (700 µL) was added to the 
column and centrifuged at a speed of 12000 × g for 30 seconds. Furthermore, a 700 µL of low 
stringency wash solution was also added to the RNA binding column and centrifuged at a speed 
of 12000 × g for 1 minute. The residual wash solution was added to thoroughly remove the 
RNA from the binding column and an additional 2 minutes centrifugation was done. The RNA 
binding column was transferred to a DNase/RNase free 1.5 mL microcentrifuge tube with a 
cap. To elute the RNA a 30 µL of the elution solution was added at middle of the membrane 
stack and allowed to soak and saturate for 1 minute prior to a 2 minutes centrifugation at a 
speed of 12000 × g. Quantification of sample was done immediately. 
3.5 Quantification 
The purity of the RNA samples was determined using the absorption ratio 260/230. Ordinarily 
the range of 260/230 absorption ratio is expected to be between 2, and 2.2. If the value for 
260/230 is found to be less than 2 it can be a possibility of contamination. However, lower 
values to approximately 1.8 are acceptable. All the samples with absorption ratios that are less 
than 1.8 were excluded for further analysis. 
A 260/280 is the primary measure of RNA and DNA purity. For this absorption ration the value 
that is considered pure for RNA samples is approximately 2.0 and 1.8 for DNA. It is of 
importance to note that the concentrations of the samples do not give an idea about the integrity 
and purity of the samples. Hence, the study relied on the absorption ratios. 
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Nanodrop 2000c spectrophotometer was used to measure the concentration and quality of RNA 
for all samples. The samples were immediately stored in a -80 °C freezer after determining 
RNA concentrations. 
3.6 Reverse transcription 
The total messenger RNA extracted from the samples were reverse transcribed into 
complementary deoxyribonucleic acid (cDNA) using the iScriptTM cDNA synthesis kit (Bio-
Rad, USA). Below is the table showing the components and volume per reaction required to 
synthesize cDNA. A 1 µg is the minimum requirement to synthesize cDNA in accordance with 
the manufacturer’s manual instructions. In this study all the reagents were multiplied by two to 
get 2 µg which is the maximum that can be used for a polymerase chain reaction (PCR) run 
(see table 2 below for the reagents). The total volume added to the RNase/DNase free tubes 
was 40 µL instead of 20 µg. The above-mentioned procedure was performed on ice. Thereafter, 
the RNA samples with reagents added were incubated using iCycler (see table 3.3 below). 
The total messenger RNA extracted from the samples were reverse transcribed into cDNA 
using the iScriptTM cDNA synthesis kit (Bio-Rad, USA). Below is the table showing the 
components and volume per reaction required to synthesize cDNA. 
 
Table 2: Reverse-transcription into cDNA. 
Reagents                                                  Volume per tube 
5× iScript reaction mix                             4 µl 
iScript reverse transcriptase                      1 µl 
Nuclease free water                                   x µl 
RNA template                                            y µl 
 
The letter “x” and “y” represents the volume required for the water or RNA template 
respectively, depending on the amount needed to have 1 µg of RNA in  each reaction tube. The 
incubation of a complete reaction was done in four steps using an iCycler (Bio-Rad, USA) 
machine (see table 3 below). Each cDNA sample was analysed with Nanodrop 2000c 
spectrophotometer to check the quality and purity of the samples, concentrations and the 
sharpness of a peak formed to see if there is no degradation of the samples. Immediately after 
analysis with Nanodrop 2000c spectrophotometer the cDNA was stored at -20 °C for qPCR. 
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Table 3: A table showing the incubation period and temperatures needed for cDNA. 
Steps                    Temperature (°C)              Time (Minutes) 
1                                25                                     5 
2                                42                                     30 
3                                85                                     5 
4                                 4                                      holding (optional)   
 
3.7 Quantitative polymerase chain reaction (qPCR) 
National Center for Biotechnology Information (NCBI) primer blast tool was utilised to design 
and verify all the genes of interest and reference genes (see table 5). The genes were 
synthesized by Inqaba biotec™, South Africa, Pretoria). 
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Table 4: The primer sequence of all the genes of interest and reference genes with the melting 
temperatures. FV: reverse primer; FW: forward primer. 
Protein Gene Primer Sequence (5'-3')                                                         Annealing 
Temperature 
Reference genes 
CanX CanX FW: GAAAGTGGGAGGTAGATGAATG 
RV: GCTTGTTCAGTTTAGCAGAGATG                            
60°C 
Tata-
binding 
Tata-
binding 
FW:CGGAGAAGTGAAGCCCGTAG 
RV:CTTCAAAGCCAGCACGGTTC 
61°C 
ATP5B ATP5B FW: AAAGAATCACCACCACCAAGAAG 
RV: GACAGCACAGTAGTAGCATCCA 
60°C 
YWHAZ YWHAZ FW: CCCACTCCGGACACAGAATATC 
RV: TCATCGTATCGCTCTGCCTG 
60°C 
Target genes 
Cyp7a1 Cyp7a1 FW: GCTTTACAGAGTGCTGGCCAA 
RV: RW: CTGTCTAGTACCGGCAGGTCATT 
61.7 
Cyp27a1 Cyp27a1 FW: CCTTTGGGACTCGCACCA 
RV: RW: GCCCTCCTGTCTCATCACTTG 
62.5 
Cyp8b1 Cyp8b1 FW: AGCTTCAAAGTGAGGAGTGG 
RV: AAGGACCAGGTCAAATAGCC 
61.4 
Baat Baat FW: CTGTCGAACTACGGTTTTGGCGAA 
RV: TCAGGCCTGTGACCCGGATA 
59.3 
Bsep Abcb11 FW: GCCATTGTGCGAGATCCTAAA 
RV: TGCAGGTCCGACCCTCTCT 
58.6 
Fxr Nr1h4 FW: GAAAGAGCGGCATCTCCGA 
RV: TGCTGTGAGCAGAGCGTACTCTT 
61.2  
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Table 5: A table below indicate the reaction components and values for the qPCR run. 
Reaction Volume per reaction Remarks 
iQ SYBR Green Supermix 10 µl  
Primer 1 1 µl 500 nM (final concentration) 
Primer 2 1 µl 500 nM (final concentration) 
Sterile water 3 µl  
DNA template 5 µl 1 in 5 dilutions 
Total 20 µl  
 
The procedure below was followed to prepare the PCR plate. NTC (no template control), all 
standards and all samples were done in duplicate. 
Both forward primer (10 µl) and reverse primer (10 µl) were each diluted with 90 µl nuclease 
free water (1:9). The supermix was vortexed for 15 seconds and thereafter 970 µl of supermix 
was taken out into a 2 ml RNAse free autoclaved tube. Added both diluted forward and reverse 
primers (97 µl each) to 970 µl supermix. Thereafter, added 97×3=291 µl nuclease free water 
to the reaction of supermix, diluted forward and reverse primers. The total reaction mixture 
that was added to the PCR plate was 1455 µl. For each well add 5 µl of DNA template followed 
by 15 µl of the reaction mix (supermix, diluted forward and reverse primers and sterile water). 
The samples were added in duplicates. This was done in duplet for each sample. All wells were 
closed by putting a transparent tape on top of the PCR plate. After closing the PCR plate, the 
reaction components were Centrifuged at 1200 rpm for 2 minutes. Lastly, the PCR plate was 
placed into a qPCR machine (CFX connect, Bio-Rad), set the correct plate and protocol and 
started the run. The above-mentioned procedural steps were performed under a sterile 
environment inside a laminar flow hood to avoid contamination of the cDNA samples by the 
atmospheric microorganisms. 
The protocol for each run was as follows: the reaction was hot started at 95°C for 3 minutes, 
followed by 40 cycles at 95°C for 30 seconds, then 60 seconds for annealing and extension at 
the optimized annealing temperatures for specific primers. This was followed by a melt curve: 
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started at 95°C for 30 seconds, then 48°C for 30 seconds and a continuous increase of 1°C after 
every 30 seconds for 47 times for complete melting of DNA 
3.8 Statistical analysis 
Biogazelle qbase+ (qbase) is an essential software programme that was used to analyse the 
qPCR runs. The vital component of this computer program includes the following; 
➢ Statistics 
➢ geNorm analysis (to choose stable reference genes) 
➢ Post-PCR quality assurance 
➢ Normalization of runs 
During analysis of genes the restrictions were rectified by using multiple reference genes. All 
the results were analysed with two-way ANOVA, followed by Wilcoxon–Mann–Whitney  post 
hoc analysis test. 
3.8.1 The theory behind the graphical representation of data 
All the results are represented in graphs with values after statistical analysis with qbase 
software (See Annexure A). In this study the expression was presented in two different ways: 
A) The one graph showing the mean Calculated Normalized Relative Quantity (CNRQ) 
and standard deviation 
B) The other graph showing fold change from control group. 
 Fold change is a way to describe how much a quantity changes between an original and a 
subsequent measurement. It is defined as the ratio the between the two quantities; Therefore, 
the control is always plus or minus 1. When a fold change from control group is greater than 
1, the expression is shown in the positive axis indicating an increase in the expression whereas 
when its negative is shown in the negative axis indicating a decrease in the expression (see 
figure 9 below). When the original gene activity (mRNA expression) doubles, it will have a 
two-fold change. This doubling in expression of mRNA (two-fold expression) will make a 
significant difference on the protein expression. A fold change greater than 2 (from control) is 
regarded as a meaningful change although the change may not be statistically significant. 
  
9 
 
A 
 
B 
Figure 9: Figure A shows mean CNRQ and standard deviations. Figure B shows fold change. 
Blue indicates the values of control, which are always 1 (or minus 1 if the value is decreased). 
Orange indicates the fold change from control. 
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CHAPTER 4 
RESULTS AND DISCUSSION 
4.1 Introduction 
Rat liver samples of two previous experiments (Adewale, 2018) and (Cairncross, 2015) were 
used to investigate bile formation. 
Initially there were 46 samples which originated from 8 treatment groups (see Table 6 below). 
During extraction of RNA 4 samples (p.14 AuNP 3 to 6) were lost as a result of a centrifuge 
machine that broke down the tubes. The centrifuge machine was changed, and the process of 
extraction worked without causing any further damage to the samples. Out of the 41 remaining 
samples one sample (L p.C AuNP 5) was removed due to unacceptable contamination 
identified during quantification by a Nanodrop spectrophotometer (see Table 6 below). It was 
not possible to replace the damaged samples as indicated that they were collected in the study 
of Dr. Adewale and the samples stored in RNAlater were already cut to a size of approximately 
100 mg. Whole sample was used for RNA extraction at a time. 
4.2 RNA extraction 
RNA was extracted from all the samples. The integrity and quantity were determined with a 
NanoDrop 2000c Spectrophotometer. A ratio 260/280 with values above 1.8 is acceptable 
whereas those that are below 1.8 are contaminated with proteins. The acceptable value for 
260/230 is 1.5 and above whereas those that are below 1.5 indicated that samples were 
degraded and were not suitable to use for qPCR analysis. 
Table 6: RNA quantification and quality (NanoDrop 2000c Spectrophotometer). 
SAMPLE 
NAMES 
TREATMENT 
DESCRIPTION 
CONCEN-
TRATIONS 
(ng/µl) 
RNA 
(260/230)2 
RNA 
(260/280)2 
HL 1 1-day control  4956,9 2,11 2,07 
HL 2 1-day control  5698,7 2,02 2,01 
HL 3 1-day control  821,0 2,05 2,14 
HL 4 1-day control  1068,6 2,19 2,16 
HL 5 1-day control  3575,8 2,14 2,09 
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HL 6 1-day control  707,5 2,13 2,15 
     
2HL 1 p.C 1 1-day p.C-AuNPs 1647,7 2,08 2,11 
2HL 2 p.C 2 1-day p.C-AuNPs 176,0 2.08 2.09 
2HL 3 p.C 3 1-day p.C-AuNPs 1756,0 2,13 2,11 
2HL 4 p.C4 1-day p.C-AuNPs 3260,7 2,19 2,11 
2HL 5 p.C5 1-day p.C-AuNPs 1345,8 2,06 2,04 
2HL 6 p.C6 1-day p.C-AuNPs 2157,7 2,11 2,08 
     
L control 1 14 days control  191,4 2,15 2,11 
L control 2 14 days control  3159,4 2,2 2,13 
L control 3 14 days control  1941,5 2,11 2,11 
L control 4 14 days control  1237,1 2,18 2,14 
L control 5 14 days control  744,1 2,24 2,14 
L control 6 14 days control  1585,1 2,18 2,14 
         
L cAuNPs 1 14 days citrate-AuNPs 771,5 2,2 2,06 
L cAuNPs 2 14 days citrate-AuNPs 1084,0 2,35 2,15 
L cAuNPs 3 14 days citrate-AuNPs 440,0 2,25 2,12 
L cAuNPs 4 14 days citrate-AuNPs 917,6 2,33 2,13 
L cAuNPs 5 14 days citrate-AuNPs 1490,5 2,25 2,13 
     
L PEG AuNPs 1 14 days PEG-AuNPs 199,5 2,22 2,11 
L PEG AuNPs 2 14 days PEG-AuNPs 218,3 1,93 1,82 
L PEG AuNPs 3 14 days PEG-AuNPs 126,3 2,11 2,16 
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L PEG AuNPs 4 14 days PEG-AuNPs 119,8 2,55 2,17 
L PEG AuNPs 5 14 days PEG-AuNPs 292,2 2,35 2,14 
L PEG AuNPs 6 14 days PEG-AuNPs 353,2 2,18 2,13 
         
PL AuNPs 1 14 days p.L-AuNPs 537,8 2,13 2,14 
PL AuNPs 2 14 days p.L-AuNPs 208,7 2,14 2,12 
PL AuNPs 3 14 days p.L-AuNPs 221,2 2,16 2,13 
PL AuNPs 4 14 days p.L-AuNPs 118 2,32 2,11 
PL AuNPs 5 14 days p.L-AuNPs 255,8 2,16 2,14 
PL AuNPs 6 14 days p.L-AuNPs 291,6 2,16 2,14 
         
p.14 AuNPs 1 14 days p.14-AuNPs 331,5 2,07 2,14 
p.14 AuNPs 2 14 days p.14-AuNPs 519,0 2,22 2,13 
p.14 AuNPs 3 14 days p.14-AuNPs 0 (vial broke) - - 
p.14 AuNPs 4 14 days p.14-AuNPs 0 (vial broke) - - 
p.14 AuNPs 5 14 days p.14-AuNPs 0 (vial broke) - - 
p.14 AuNPs 6 14 days p.14-AuNPs 0 (vial broke) - - 
     
L p.C AuNPs 1 14 days p.C-AuNPs 475,8 1,92 2,11 
L p.C AuNPs 2 14 days p.C-AuNPs 271,9 1,87 2,13 
L p.C AuNPs 3 14 days p.C-AuNPs 226,8 2,41 2,13 
L p.C AuNPs 4 14 days p.C-AuNPs 145,4 2,14 2,12 
L p.C AuNPs 5 14 days p.C-AuNPs 38,6 0,59 1,4 
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Sample L p.C AuNP 5 did not meet integrity criteria and was removed from experiment for 
further analysis. The whole sample stored in RNAlater was used for RNA extraction and 
therefore another extraction was not possible. RNA was extracted from 8 samples at a time. 
All the other samples in the extraction batch met the integrity quality. It is therefore suspected 
that the integrity of the sample was compromised with sampling. It is very important that 
samples used for RNA extraction must be collected within minutes after the animal died. It is 
further important, that if the sample is stored in RNAlater, that the whole sample is immediately 
covered with RNAlater. 
4.3 qPCR analysis 
Forty-one samples were analysed. However, sample 2HL 2 was automatically excluded by 
qPCR from analysis, upon a further investigation it was recorded and found that during 
pipetting the pipette tip touched the surface of a qPCR plate which could have resulted in 
contamination of the whole sample. The sample 2HL 6 (for Cyp27a1 only) was also excluded 
for unknown reason because the integrity of the sample was not affected. Nevertheless, this did 
not affect the statistical result for Cyp27a1 as the group had 5 more samples for analysis. This 
means on one 96-well plate all the samples in duplicate could fit, which consists of 
Group 1: 1-day control (n=6) 
Group 2: 1-day p.C-AuNPs (n=5) 
Group 3: 14 days control (n=6) 
Group 4: 14 days citrate-AuNPs (n=5) 
Group 5: 14 days PEG-AuNPs (n=6) 
Group 6: 14 days p.L-AuNPs (n=6) 
Group 7: 14 days p.14-AuNPs (n=2) 
Group 8: 14 days p.C-AuNPs (n=4) 
NTC: RNAse free water 
Negative control: randomly chosen RNA samples – different samples for each plate 
Standard curve 
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4.3.1 Reference genes 
mRNA expression for four reference genes (Tata, CanX, ATP5B and YWHAZ) were 
determined and all four were determined at less than 30 cycles. When analysed with qbase the 
M and CV values were 1.368 and 0.558 respectively. Tata binding protein was the most 
unstable gene and when it was removed, the average M and CV values was 0.828 and 0.334 
respectively. 
4.3.2 Genes of interest 
Six genes of interest were determined: Cyp7a1, Cyp27a1, Cyp8b1, Baat, Bsep and Fxr. The 
qbase+ computer program was used to analyse the results and the program indicated whether 
there is a differential mRNA expression between samples or not. The six genes of interest were 
normalised to the average of the specific genes, using the three reference genes and expressed 
as Cyp7a1 CNRQ, Cyp27a1 CNRQ, Cyp8b1 CNRQ, Baat CNRQ, Bsep CNRQ, Fxr CNRQ. 
The mean CNRQ and standard deviation were calculated. The outlier test of GraphPad was 
used to identify outliers. The results for rat 1 (control 1) was furthest from the rest for Baat, 
Bsep and Fxr although it was not significant. Rat 6 (p.C 4) was furthest for Baat, Cyp27a1 and 
Fxr. Rat 6 (p.C 4) it was a significant outlier (p<0.05) for gene Bsep. These samples were the 
furthest from the average for the other genes, although not significant outliers. It was therefore 
decided not to include them due to some other reason rat 1 (control 1) and rat 6 (p.C 4) did not 
represent the results of groups 14 days control and 14 days p.C and therefore all gene analysis, 
rat 1 (control 1) and rat 6 (p.C 4) were removed. See appendix B for the details. 
Results below indicate the mean CNRQ for each gene and the significant differences. The main 
interest of this project is the results obtained after 14 days from rats that were treated with 
different functionalised groups to 14 nm AuNPs. To evaluate whether gene changes can already 
happen in the liver after 1 day two groups were added (1-day control and 1-day p.C) from an 
experiment of Cairncross (2016). These two groups were from different experiments and can 
therefore not be directly compared to rats in groups that were sacrificed 14 days after injection. 
To clarify the differences the groups sacrificed after 1 day are represented in green on the 
graphs and the groups sacrificed after 14 days are represented in blue on the graphs. Significant 
differences are indicated on the graphs. Note groups sacrificed after 1 day were compared to 
each other and groups sacrificed after 14 days were compared to each other. 
Results were also presented as fold change. Fold change measures a shift from control value 
or initial value to a final value of a quantity (final value/initial value). mRNA mean CNRQ 
value that changes from 0,5 to 1 means the mRNA value has doubled (2-fold change) and can 
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therefore have a significant effect on the specific protein synthesis.  In molecular research two-
fold change or more should be noted as a change. 
In the graphs the blue colour represents the control indicating no change in the mRNA 
expression level of a gene. The value of control remains plus or minus 1 throughout. A shift 
from the control in vertical axis shows a change and it is represented by an orange colour. 
4.4 CYP7A1 
The trend in figure 10 indicates that the mRNA expression level of Cyp7a1 generally decreases 
as the number of days increases after treatment by different peptide-AuNPs with exception to 
14 days p.14-AuNPs. Although 1-day p.C-AuNPs shows a slight mean CNRQ increase as 
compared to the normal and at 14 days p.C-AuNPs showed a decrease compare to 14 days 
normal, the differences were not significant. 
Figure 11 There was a slight increase in fold change between 1-day control and 1-day p.C-
AuNPs whereas 14 days p.C-AuNPs decreased by approximately 2-fold. The mRNA 
expression levels among 14 days citrate-AuNPs, 14 days PEG-AuNPs, 14 days p.L-AuNPs and 
14 days p.C-AuNPs decreased whereas 14 days p.14-AuNPs increased slightly. The differences 
in fold change among the groups showed no significance. Treatment 14 days p.L-AuNPs had 
a major decrease of 2.95-fold decrease as compared to 14 days control. This down-regulation 
was not statistically significant although the decrease was almost 3-fold and should be noted 
as a decrease. 
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Figure 10: Mean CNRQ of Cyp7a1, normalized to average. The standard deviation is shown 
by error bars. 
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Figure 11: Fold change of liver Cyp7a1-transcripts from control groups for 1 day and 14 days 
respectively. 1: 1-day control (n=6); 2: 1-day p.C-AuNPs (n=5); 3: 14 days control (n=6); 4: 
14 days citrate-AuNPs (n=5); 5: 14 days PEG-AuNPs (n=6); 6: 14 days p.L-AuNPs (n=6); 7: 
14 days p.14-AuNPs (n=2); 8: 14 days p.C-AuNPs (n=4). 
In the endoplasmic reticulum Cyp7a1 which is regarded as the rate-limiting enzyme that 
converts cholesterol into 7α-hydroxycholesterol (Li and Li, 2017). The Cyp7a1 is also involved 
as a line of defence by detecting signals from the gut concerning the toxicity of bile (Gilardi et 
al., 2007). In pharmacology certain drugs target the negative feedback mechanism that 
regulates Cyp7a1 in order to reduce cholesterol. From the above graphs of Cyp7a1 expression 
level it was clear that 14 days p.L-AuNPs (6) had almost a 3-fold decrease although it was not 
significant. This decrease of Cyp7a1 mRNA expression level is expected to decrease bile acid 
synthesis. In this case the classical pathway is negatively affected by 14 days p.L-AuNPs for 
increased conversion of cholesterol into 7α-hydroxycholesterol. 
The reason for the decrease of Cyp7a1 was not expected since it would mean that secretion of 
CA and bile acid flow could be influenced negatively, which would affect the excretion of 
AuNPs via the hepatobiliary system negatively. The inhibitory trend on Cyp7a1 mRNA 
expression could be because of the AuNPs and that p.L has an additive effect, however 14 days 
p.14-AuNP tends to increase the synthesis of Cyp7a1 and therefore this possibility will be 
treated with caution. Ellis (2006) illustrated that T3 can inhibit Cyp7a1 mRNA expression. 
FXR can also inhibit the expression of Cyp7a1 mRNA expression as part of its negative 
feedback function. These last two possibilities will be discussed further as other genes in the 
hepatobiliary pathway are discussed below  
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4.5 CYP27A1 
The trend in figure 12 below indicates that the mRNA expression level of Cyp27a1 is nearly 
constant with a slight difference for all the treatment groups. Although there was a 0.5 mean 
CNRQ increase for 1-day p.C the difference was not significant. 
In figure 13 below there was a slight increase in fold change between 1-day control (group 1) 
and 1-day p.C-AuNPs (group 2) whereas 14 days PEG-AuNPs (group 5), 14 days p.14-AuNPs 
(group 7) and 14-days p.C-AuNPs decreased. The differences in fold change among the groups 
were not significant. There was a slight increase in fold change of groups 4 and 6 was also not 
significant. 
 
Figure 12: Mean CNRQ of Cyp27a1, normalized to the average. There were significances with 
the control groups. The standard deviation is illustrated by error bars.  
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Figure 13: Fold change of liver Cyp27a1-transcripts from control groups for 1 day and 14 days 
respectively. 1: 1-day control (n=6); 2: 1-day p.C-AuNPs (n=5); 3: 14 days control (n=6); 4: 
14 days citrate-AuNPs (n=5); 5: 14 days PEG-AuNPs (n=6); 6: 14 days p.L-AuNPs (n=6); 7: 
14 days p.14-AuNPs (n=2); 8: 14 days p.C-AuNPs (n=4). 
The amount of cholesterol substrate that reaches the inner mitochondrial membrane which is 
mediated by a group of proteins that controls the activity of CYP27A1 (Graham, 2015). The 
CYP27A1 expression level is found to be more predominant in the liver, macrophages and 
vascular endothelium. For 1-day p.C-AuNPs, the factor (change from control) is greater than 
1. It is important to note that although there were changes from control as indicated by an 
orange colour, the changes were not significant. It was clear from the graph that mRNA 
expression level of Cyp27a1 was not changed significantly and was very little affected by the 
presence of all the AuNPs. This gene forms part of an alternative pathway for the synthesis of 
bile acids by converting a cholesterol into 7α-hydroxycholesterol. 
4.6 CYP8B1 
In figure 14 the trend indicates that the mRNA expression level of Cyp8a1 increased 14 days 
after treatment with different AuNPs. When comparing 1-day p.C-AuNPs to the 14 days p.C-
AuNPs mRNA expression levels, the mean CNRQ levels were a 0.43 and 0.96 respectively, 
but the differential expression levels were not significant (control values almost the same). The 
14 days p.L-AuNPs group had a mean CNRQ that was more than double the control resulting 
in a significant difference. 
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Figure 14: Mean CNRQ of Cyp8a1, normalized to average. The significance is represented by 
c: p<0,05 compared to the control group. The standard deviation is illustrated by error bars. 
In figure 15 below the expression of Cyp8b1 mRNA of group 1-day p.C-AuNPs decreased by 
1.53-fold as compared to control group. Group 14 days p.C-AuNPs indicated a trend of slight 
increase of 1.45-fold. All 14-days samples increased the expression level of Cyp8b1 mRNA. 
Interestingly group 14 days p.L-AuNPs doubled resulting in a statistically significant 
difference c: p<0,05 and thus indicated the up-regulation of Cyp8b1. 
 
Figure 15: Fold change of liver Cyp8b1-transcripts from control groups for 1 day and 14 days 
respectively. 1: 1-day control (n=6); 2: 1-day p.C-AuNPs (n=5); 3: 14 days control (n=6); 4: 
14 days citrate-AuNPs (n=5); 5: 14 days PEG-AuNPs (n=6); 6: 14 days p.L-AuNPs (n=6); 7: 
14 days p.14-AuNPs (n=2); 8: 14 days p.C-AuNPs (n=4). The significance is represented by c: 
p<0,05 compared to the control group. 
The significant increase in mRNA expression of Cyp8b1 after treatment with 14 days p.L-
AuNPs was anticipated to cause more formation of CA in the classical pathway. 
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In the study conducted by Andersson et al. (1999) the removal of the thyroid gland of the 
experimental rats which resulted in a 4-fold increase of the mRNA expression level of Cyp8b1. 
Their results are supported by the research who found that the thyroid hormone suppresses 
CYP7A1 as well as CYP8B1. Therefore, the possible hypothesis that the NPs could have 
increased T3 secretion which could cause the decrease in Cyp7a1 mRNA expression is 
therefore rejected. It is possible that the increased Cyp8a1 is a homeostatic feedback 
mechanism followed on the lower Cyp7a1 mRNA expression. Cyp7a1 mRNA expression in 
this experiment was most decreased (almost 3-fold) and Cyp8a1 mRNA expression was most 
increased (3-fold). 
4.7 BAAT 
Figure 16 indicates that all the groups resulted in a decrease of mRNA expression levels of 
Baat. 
 
Figure 16: Expression level of Baat-transcripts in the liver tissue of Wistar rats for 1 day (green 
bars) and 14 days (blue bars) respectively. Standard deviation is indicated by the error bars. 
Figure 17 below indicates the fold change from control with 3 significant changes of gene 
expression. 
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Figure 17: A fold change of liver Baat mRNA expression vs control groups for 1 day and 14 
days respectively. 1: 1-day control (n=6); 2: 1-day p.C-AuNPs (n=5); 3: 14 days control (n=6); 
4: 14 days citrate-AuNPs (n=5); 5: 14 days PEG-AuNPs (n=6); 6: 14 days p.L-AuNPs (n=6); 
7: 14 days p.14-AuNPs (n=2); 8: 14 days p.C-AuNPs (n=4). The significance is represented by 
c: p<0,05 compared to the control group. 
All the groups resulted in a decrease of mRNA expression levels of Baat. This was the only 
gene with three significant differences namely groups 14 days PEG-AuNPs, 14 days p.L-
AuNPs and 14 days p.C-AuNPs. Group 5 (14 days PEG-AuNPs) decreased by 4.02-fold which 
caused a major decrease as compared to all other groups. The difference in fold change decrease 
from control between groups 2 (1-day p.C-AuNPs) and 8 (14 days p.C-AuNPs) is huge with 
group 8 having a significant difference whereas group 2 had a slight decrease. There was a 
down-regulation of Baat as evidenced by the three groups with significant differences. 
BAAT is a liver enzyme which is located in the peroxisomes and facilitates the conjugation of 
taurine to bile acid-CoA thioester (Wu et al., 2016). Only a slight decrease was noticed after 
one day, but it seems to be more pronounced after 14 days. The decrease happened in all groups 
that were inject with AuNPs. It is therefore expected that the AuNPs may be associated with 
the peroxisomes and that it is due to the AuNPs and not due to the functional groups. This 
aspect should be further investigated and confirmed by TEM. 
The researcher could not find any literature of any other research where Baat was determined 
in rats after AuNPs injection and therefore the implication of the decreased conjugation of bile 
acids is unclear. Aleksunes et al. (2012) described lower BAAT levels with pregnancy, but this 
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seems unrelated results. Due to the significant changes found this gene, it should be 
investigated further in future. 
4.8 BSEP 
In figure 18 the 14 days citrate group was of great concern as explained above. The error bar 
of this groups shows a high level of uncertainty which could be related the low mRNA 
expression. The spread of data in group 4 for BSEP was uneven as indicated by the standard 
deviation. Mean CNRQ for p.C during day 1 was higher than control but lower than control 
after 14 days. Group 14 days p.L-AuNPs shows a bigger increase although it was not a 
significant difference. 
 
Figure 18: Mean CNRQ of BSEP, normalized to average. The significance is represented by 
c: p<0,05 compared to the control group. The standard deviation is illustrated by error bars. 
Figure 19 shows a major significant change of the citrate group whereas other groups showed 
no major change. 
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Figure 19: Fold change of liver Bsep mRNA expression vs control groups for 1 day and 14 
days respectively. 1: 1-day control (n=6); 2: 1-day p.C-AuNPs (n=5); 3: 14 days control (n=6); 
4: 14 days citrate-AuNPs (n=5); 5: 14 days PEG-AuNPs (n=6); 6: 14 days p.L-AuNPs (n=6); 
7: 14 days p.14-AuNPs (n=2); 8: 14 days p.C-AuNPs (n=4). The significance is represented by 
c: p<0,05 compared to the control group. 
BSEP is described as the primary canalicular transporter that transports BAs and regulate the 
excretion of BAs by the hepatobiliary system. Notably, BSEP impairment is likely to cause the 
precipitation of cholesterol in the biliary system and the cause may be genetic or acquired. It is 
therefore essential for bile salts to solubilize cholesterol in bile (Baghdasaryan et al., 2014). 
Both groups 1-day control (2) and 14 days p.C-AuNPs (8) showed an increase in fold change 
that was almost equal, 2.72-fold and 2.53-fold respectively. Although it was not statistically 
significant the fold change indicates that it should be noted. It was interesting to see a huge 
decrease in fold change of group 4 (14 days citrate-AuNPs) which could be related to a specific 
rat. Group 4 (14 days citrate-AuNPs) did not show even a 2-fold change for any of the other 
genes and the 6,87-fold change of Bsep was unexpected and cannot be explained at this stage. 
4.9 Fxr 
In figure 20 mean CNRQ for 1-day p.C (0.63) is lower than the one of 14-day p.C-AuNPs 
(1.53). There was no noticeable decrease in mean CNRQ of 14-day samples as compared to 
14-days control. There was no significant difference among all the groups. 
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Figure 20: Mean CNRQ of FXR, normalized to average. The significance is represented by c: 
p<0,05 compared to the control group. The standard deviation is illustrated by error bars. 
In Figure 21 There was almost no change (1.08-fold decrease) in the fold change of group 2 
(1-day p.C-AuNPs) as compared to an increase of 1.83-fold of group 8 (14 days p.C-AuNPs). 
 
Figure 21: Fold change of liver Fxr mRNA expression vs control groups for 1 day and 14 days 
respectively. 1: 1-day control (n=6); 2: 1-day p.C-AuNPs (n=5); 3: 14 days control (n=6); 4: 
14 days citrate-AuNPs (n=5); 5: 14 days PEG-AuNPs (n=6); 6: 14 days p.L-AuNPs (n=6); 7: 
14 days p.14-AuNPs (n=2); 8: 14 days p.C-AuNPs (n=4). 
It is Interesting to note that all the 14-day groups had an increase in fold change from control 
group. The differences in fold change among the 14-day treatments was approximately equal 
(about 1.5-fold increase) with a slight difference in group 8. FXR forms part of nuclear 
receptors regulating genes responsible for cell cycle and inflammatory genes. It is more 
predominant in the liver and kidneys (Magdy et al., 2018). Furthermore, it is known for its key 
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functions in the digestive system such as transport, synthesis and secretion of bile acid (Chen 
et al., 2018). There is an increasing information suggesting a relationship between the 
modulation of FXR activity and a decrease of proinflammatory mediators in the intestines, 
which leads to a reduction of epithelial permeability and inflammation in the digestive tract 
(Mosińska et al., 2018). FXR is involved in other metabolic pathways, such as modulation of 
fats digestion and glucose. Therefore, metabolic homeostasis can be influenced by either 
inhibition or activation of FXR (Matsubara et al., 2013). The changes in FXR mRNA 
expression showed such small changes that it is not expected the AuNPs treatment will have 
any negative effects on the metabolic homeostasis of an individual. FXR can also have a 
negative feedback effect on the synthesis of CYP7A1. The effect on the Fxr in this experiment 
was so small and similar amongst the different treatment groups that there is no reason to expect 
that FXR has a negative feedback effect on CYP7A1.  
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     CHAPTER 5 
     CONCLUSION 
5.1 Conclusion 
The aim of the present study was to investigate bile formation in Wistar rats for the excretion 
of injected AuNPs. This study used two groups of liver samples (1 day after AuNPs injection 
and 14 days after AuNPs injection) to evaluate if there would be a change in bile synthesis 
and/or secretion after AuNPs intravenous injection. Measuring the formation of bile is difficult 
and therefore this study relied on qPCR by measuring the gene expression of transporters and 
enzymes  in the biliary system of the liver. 
One of the most important findings in this study, is that different capping agents and functional 
conjugates (peptides) AuNPs affect genes responsible for the formation of bile acids 
differently. When analysing genes of the enterohepatic circulation carefully, Fxr plays a key 
role in the negative feedback mechanism to maintain homeostasis of bile acids in the gut. In 
this study there were no significant changes in the mRNA expression level of this gene (Fxr), 
therefore the changes in this study were due to the negative feedback of Fxr. Baat had a major 
down-regulation, but the reason at this stage is unknown. It requires further investigation by 
using other molecular techniques such as protein analysis. 
This was the first study to investigate bile formation in the history of nanoparticle use. 
5.2 Limitations 
This is a novel investigation in nanoscience and seems to be important. This study was done as 
part of a coursework degree programme and therefore limited research time was available to 
extend the research. This should therefore be seen as a pilot project that needs follow-up, 
especially with confirmation on the protein expression of enzymes like CYP7A1 and BAAT 
as well as the transporter BSEP.  
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Appendix A 
A.1 Ethics approval for using animals (Dr Adewale, O.B) 
The study of Dr Adewale, O.B (2018) involved 36 male Wistar rats aged 12 weeks. All the rats were collected from the animal institute at North 
West University. Nelson Mandela University Research Ethics Committee issued an approval for animal procedures (A15-SCI-BCM-002). These 
rats were housed in a conducive environment that provides a 12-hour light-dark cycle. The rats were given ad lib food and water in a house with 
a regulated temperature of about 22 °C (± 2 °C). 
A.2 Groupings of animals 
The acute toxicity of AuNPs was investigated in this experiment 14 days after a single intravenous injection. The animals were classified into six 
groups with each group having six animals. The first group was a control for the experiment, and it was given 1 X phosphate-buffered saline 
(PBS), the other five remaining groups were given a single intravenous injection (100 µg/kg of bodyweight) of citrate capped-AuNPs, PEG capped-
AuNPs, p.C-PEG-AuNPs, p.L-PEG-AuNPs, or p.14-PEG-AuNPs, respectively. 
The dose used during this experiment was determined in our laboratory to target colorectal cancer tumour in Wistar rats. The dose range considered 
as safe was 3-373 µg/kg (Adewale, 2018). A constant dosing was ensured by measuring the body weight of each rat 1 day after injection and 
subsequently for every week until the end of the experiment. According to Adewale (2018) the rats were observed in order check their 
reactions/symptoms of toxicity, mortality and health status. 
A.3 Sacrifice and organ harvesting of Wistar rats 
The sacrifice of the rats was done after an overnight fasting. The ice-cold physiological saline (0.9% NaCl) was utilised to rinse the removed 
organs such as liver , spleen, kidneys, colon, heart and brain before measuring their weight. The removed organs were grouped according to the 
of the analysis to be performed. A 10% neutral phosphate buffered-formalin was used to store pieces of the removed organs, each was 3 mm2. A 
small portion of tissues (1 mm2 were kept in a PBS solution (2% paraformaldehyde (pH 7.4, 0.5 mL) and 2.5% glutaraldehyde) to be analysed by 
ii 
 
high resolution transmission electron microscopy at a temperature of 4 °C. Another portion of tissue (3 mm2 each tissue) which was used for gene 
analysis was stored in RNAlater at a temperature of 4 °C (0.5 mL) for gene analyses. The remaining pieces of the removed organs were wrapped 
with aluminium foil and it was frozen instantly with liquid nitrogen prior to storage in a -80 °C freezer. 
A.4 Ethics approval for animal studies (Ms Cairncross, L.C) 
The experimental procedure of using animals was approved by Nelson Mandela University Research Ethics Committee (A13-SCI-ZOO-013). 
A.5 Animal care 
Laboratory male Wistar rats which were obtained from North West University animal facility were used for the study of Ms Cairncross, L.C. 
These rats were kept in a temperature-controlled cages 22°C (± 3°C) in accordance with the South African Standards. Each cage housed five rats. 
The rats were in the presence of light for 12 hours and darkness for 12 hours. The rats were nourished with ad libitum and water. 
A.6 Experimental design 
Thirty-five laboratory Wistar rats were grouped into six groups. The allocation was made in such a way that the 3 groups are used as control 
whereas the remaining 3 groups were used as experimental groups. Colorectal cancer was induced in 3 experimental groups (groups 1, 2 and 3) 
with p.C-AuNPs, p.14-AuNPs and p.L-AuNPs respectively. The fourth and the fifth groups were treated with two peptide-AuNPs (p.C and p.14). 
They were preserved as healthy groups. According to the study of Cairncross (2015) this procedure evaluated the distribution of the peptide-
AuNPs of groups 4 and 5. The last group (group 6) was not treated and it was referred to as a healthy non-treated. 
A.7 Sacrifice and harvesting of organs 
The weight measurement of the rats was taken, and they were injected intramuscularly with Ketamine. After a loss of sensation, cardiac puncture 
was performed resulting in a hypovolemic death. See the images below. The study was based more on colon than other organs, this resulted in 
other organs being removed rapidly. All pieces of the removed tissues of 1 mm3 were fixed for 1 day. 
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A.8 Samples used in the study of Mr S.T Thole (this study) 
In the Cairncross study (2015) rats in groups 1 to 3 were treated to induce colorectal cancer. One does not know what the effect of this treatment 
may be on the hepatobiliary system was and therefore only two control groups were used in this study to give a preliminary of what happens in 
the biliary system 1-day post AuNPs injection (p.C-PEG-AuNPs  (group 4) and healthy controls (group 6) were used and in this study named 
group 1 and 2). Groups 3 to 8 in this study are rats from Adewale’s study (2018).  
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Appendix B 
Table B.1: Statistical analysis of genes of interest showing the significance between different groups. 
Target p r2 Property Comparison  
(group/group) 
Ratio 95% 
ci 
low 
95% 
ci 
high 
Significant Group Mean Standard 
Deviation 
95% 
value ci 
low 
95% 
value ci 
high 
datapoints 
Cyp7a1           
0,00  
          
0,60  
 
Groupings  
           
    
 1/2            
0,66  
                 
0,20  
                   
2,17  
No   1            
1,86  
                                   
0,24  
                              
1,05  
                        
3,31  
         
6,00      
 1/3            
1,58  
                 
0,48  
                   
5,18  
No   2            
2,82  
                                   
0,12  
                              
1,98  
                        
4,02  
         
5,00      
 1/4            
2,88  
                 
0,88  
                   
9,46  
No   3            
1,18  
                                   
0,11  
                              
0,86  
                        
1,63  
         
5,00      
 1/5      
2,66  
                 
0,86  
                   
8,29  
No   4            
0,65  
                                   
0,33  
                              
0,25  
                        
1,67  
         
5,00  
               
    
 1/6            
4,65  
                 
1,49  
                
14,46  
Yes   5            
0,70  
                                   
0,31  
                              
0,33  
                        
1,48  
         
6,00      
 1/7            
0,88  
                 
0,18  
                   
4,36  
No   6            
0,40  
                                   
0,28  
                              
0,20  
                        
0,79  
         
6,00      
 1/8            
3,00  
                 
0,75  
                
12,04  
No   7            
2,13  
                                   
0,02  
                              
1,54  
                        
2,93  
         
2,00      
 2/3            
2,39  
                 
0,69  
                   
8,28  
No   8            
0,62  
                                   
0,42  
                              
0,06  
                        
6,80  
         
3,00      
 2/4            
4,36  
                 
1,26  
                
15,13  
Yes  
      
    
 2/5            
4,04  
                 
1,23  
                
13,28  
Yes  
      
    
 2/6            
7,05  
                 
2,14  
                
23,16  
Yes  
      
    
 2/7            
1,33  
                 
0,26  
                   
6,87  
No  
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4,55  
                 
1,08  
                
19,10  
Yes  
      
    
 3/4            
1,83  
                 
0,53  
                   
6,33  
No  
      
    
 3/5            
1,69  
                 
0,51  
                   
5,56  
No  
      
    
 3/6            
2,95  
                 
0,90  
                   
9,70  
No  
      
    
 3/7            
0,56  
                 
0,11  
                   
2,88  
No  
      
    
 3/8            
1,90  
                 
0,45  
                   
8,00  
No  
      
    
 4/5            
0,93  
                 
0,28  
                   
3,04  
No  
      
    
 4/6            
1,61  
                 
0,49  
                   
5,31  
No  
   
                                  
-    
  
    
 4/7            
0,30  
                 
0,06  
                   
1,58  
No  
      
    
 4/8            
1,04  
                 
0,25  
                   
4,38  
No  
      
    
 5/6            
1,74  
                 
0,56  
                   
5,43  
No  
      
    
 5/7            
0,33  
                 
0,07  
                   
1,64  
No  
      
    
 5/8            
1,13  
                 
0,28  
                   
4,52  
No  
      
    
 6/7            
0,19  
                 
0,04  
                   
0,94  
Yes  
      
    
 6/8            
0,65  
                 
0,16  
                   
2,59  
No  
      
    
 7/8            
3,43  
                 
0,57  
                
20,60  
No  
      
  
 
  
            
Cyp27a1           
0,43  
          
0,20  
 
Groupings  
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0,66  
                 
0,26  
                   
1,71  
No   1            
1,00  
                                   
0,33  
                              
0,45  
                        
2,20  
         
6,00      
 1/3            
0,99  
                 
0,41  
                   
2,39  
No   2            
1,50  
                                   
0,09  
                              
1,09  
                        
2,07  
         
4,00      
 1/4            
0,90  
                 
0,37  
                   
2,19  
No   3            
1,01  
                                   
0,11  
                              
0,75  
                        
1,38  
         
5,00      
 1/5            
1,20  
                 
0,52  
                   
2,80  
No   4            
1,11  
                                   
0,15  
                              
0,73  
                        
1,69  
         
5,00      
 1/6            
0,93  
                 
0,40  
                   
2,16  
No   5            
0,83  
                                   
0,23  
                              
0,48  
                        
1,44  
         
6,00      
 1/7            
1,44  
                 
0,43  
                   
4,75  
No   6            
1,08  
                                   
0,17  
                              
0,72  
                        
1,62  
         
6,00      
 1/8            
1,32  
                 
0,47  
                   
3,71  
No   7            
0,70  
                                   
0,01  
                              
0,52  
                        
0,92  
         
2,00      
 2/3            
1,48  
                 
0,55  
                   
3,96  
No   8            
0,76  
                                   
0,07  
                              
0,50  
                        
1,15  
         
3,00      
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1,35  
                 
0,51  
                   
3,62  
No  
      
    
 2/5            
1,81  
                 
0,70  
                   
4,66  
No  
      
    
 2/6            
1,39  
                 
0,54  
                   
3,59  
No  
      
    
 2/7            
2,16  
                 
0,61  
                   
7,69  
No  
      
    
 2/8            
1,98  
                 
0,65  
                   
6,07  
No  
      
    
 3/4            
0,91  
                 
0,36  
                   
2,31  
No  
      
    
 3/5            
1,22  
                 
0,50  
                   
2,97  
No  
      
    
 3/6            
0,94  
                 
0,39  
                   
2,29  
No  
      
    
 3/7            
1,46  
                 
0,43  
                   
4,97  
No  
      
    
 3/8            
1,34  
                 
0,46  
                   
3,90  
No  
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1,34  
                 
0,55  
                   
3,24  
No  
      
    
 4/6            
1,03  
                 
0,42  
                   
2,50  
No  
      
    
 4/7            
1,60  
                 
0,47  
                   
5,44  
No  
      
    
 4/8            
1,46  
                 
0,50  
                   
4,27  
No  
      
    
 5/6            
0,77  
                 
0,33  
                   
1,80  
No  
      
    
 5/7            
1,19  
                 
0,36  
                   
3,95  
No  
      
    
 5/8            
1,10  
                 
0,39  
                   
3,09  
No  
      
    
 6/7            
1,55  
                 
0,47  
                   
5,13  
No  
      
    
 6/8            
1,42  
                 
0,50  
                   
4,00  
No  
      
    
 7/8            
0,92  
                 
0,24  
                   
3,49  
No  
      
               
Cyp8b1           
0,00  
          
0,64  
 
Groupings  
           
    
 1/2            
1,53  
                 
0,64  
                   
3,65  
No   1            
0,66  
                                   
0,15  
                              
0,46  
                        
0,96  
         
6,00      
 1/3            
1,00  
                 
0,42  
                   
2,39  
No   2            
0,43  
                                   
0,16  
                              
0,27  
                        
0,69  
         
5,00      
 1/4            
0,52  
                 
0,22  
                   
1,25  
No   3            
0,66  
                                   
0,23  
                              
0,34  
                        
1,27  
         
5,00      
 1/5            
0,43  
                 
0,19  
                   
0,99  
Yes   4            
1,26  
                                   
0,16  
                              
0,79  
                        
2,02  
         
5,00      
 1/6            
0,32  
                 
0,14  
                   
0,74  
Yes   5            
1,54  
                                   
0,17  
                              
1,02  
                        
2,33  
         
6,00      
 1/7            
0,44  
                 
0,14  
                   
1,42  
No   6            
2,04  
                                   
0,28  
                              
1,04  
                        
4,02  
         
6,00  
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0,69  
                 
0,25  
                   
1,90  
No   7            
1,51  
                                   
0,01  
                              
1,11  
                        
2,05  
         
2,00      
 2/3            
0,65  
                 
0,26  
                   
1,62  
No   8            
0,96  
                                   
0,11  
                              
0,51  
                        
1,81  
         
3,00      
 2/4            
0,34  
                 
0,14  
                   
0,85  
Yes  
      
    
 2/5            
0,28  
                 
0,12  
                   
0,67  
Yes  
      
    
 2/6            
0,21  
                 
0,09  
                   
0,51  
Yes  
      
    
 2/7            
0,29  
                 
0,09  
                   
0,95  
Yes  
      
    
 2/8            
0,45  
                 
0,16  
                   
1,29  
No  
      
    
 3/4            
0,52  
                 
0,21  
                   
1,30  
No  
      
    
 3/5            
0,43  
                 
0,18  
                   
1,02  
No  
      
    
 3/6            
0,32  
                 
0,14  
                   
0,77  
Yes  
      
    
 3/7            
0,44  
                 
0,13  
                   
1,46  
No  
      
    
 3/8            
0,69  
                 
0,24  
                   
1,96  
No  
      
    
 4/5            
0,82  
                 
0,34  
                   
1,96  
No  
      
    
 4/6            
0,62  
                 
0,26  
                   
1,48  
No  
      
    
 4/7            
0,84  
                 
0,25  
                   
2,78  
No  
      
    
 4/8            
1,32  
                 
0,46  
                   
3,76  
No  
      
    
 5/6            
0,75  
                 
0,33  
                   
1,73  
No  
      
    
 5/7            
1,02  
                 
0,32  
                   
3,29  
No  
      
ix 
 
    
 5/8            
1,60  
                 
0,58  
                   
4,42  
No  
      
    
 6/7            
1,35  
                 
0,42  
                   
4,37  
No  
      
    
 6/8            
2,13  
                 
0,77  
                   
5,88  
No  
      
    
 7/8            
1,57  
                 
0,42  
                   
5,83  
No  
      
               
Baat           
0,00  
          
0,56  
 
Groupings  
           
    
 1/2            
1,07  
                 
0,36  
                   
3,15  
No   1            
1,55  
                                   
0,31  
                              
0,73  
                        
3,27  
         
6,00      
 1/3            
0,78  
                 
0,26  
                   
2,29  
No   2            
1,45  
                                   
0,24  
                              
0,74  
                        
2,84  
         
5,00      
 1/4            
0,97  
                 
0,33  
                   
2,87  
No   3            
1,99  
                                   
0,22  
                              
1,06  
                        
3,75  
         
5,00      
 1/5            
3,12  
                 
1,11  
                   
8,75  
Yes   4            
1,59  
                                   
0,17  
                              
0,98  
                        
2,60  
         
5,00      
 1/6            
2,60  
                 
0,93  
                   
7,30  
No   5            
0,50  
                                   
0,20  
                              
0,28  
                        
0,88  
         
6,00      
 1/7            
2,53  
                 
0,59  
                
10,89  
No   6            
0,59  
                                   
0,28  
                              
0,30  
                        
1,17  
         
6,00      
 1/8            
2,99  
                 
0,84  
                
10,56  
No   7            
0,61  
                                   
0,09  
                              
0,09  
                        
4,30  
         
2,00      
 2/3            
0,73  
                 
0,23  
                   
2,25  
No   8            
0,52  
                                   
0,06  
                              
0,38  
                        
0,72  
         
3,00      
 2/4            
0,91  
                 
0,29  
                   
2,81  
No  
      
    
 2/5            
2,92  
                 
0,99  
                   
8,61  
No  
      
    
 2/6            
2,44  
                 
0,83  
                   
7,19  
No  
      
    
 2/7            
2,37  
                 
0,53  
                
10,57  
No  
      
x 
 
    
 2/8            
2,79  
                 
0,76  
                
10,29  
No  
      
    
 3/4            
1,25  
                 
0,40  
                   
3,87  
No  
      
    
 3/5            
4,02  
                 
1,36  
                
11,85  
Yes  
      
    
 3/6            
3,35  
                 
1,14  
                   
9,89  
Yes  
      
    
 3/7            
3,26  
                 
0,73  
                
14,54  
No  
      
    
 3/8            
3,84  
                 
1,04  
                
14,17  
Yes  
      
    
 4/5            
3,21  
                 
1,09  
                   
9,47  
Yes  
      
    
 4/6            
2,68  
                 
0,91  
                   
7,90  
No  
      
    
 4/7            
2,61  
                 
0,58  
                
11,62  
No  
      
    
 4/8            
3,07  
                 
0,83  
                
11,32  
No  
      
    
 5/6            
0,83  
                 
0,30  
                   
2,34  
No  
      
    
 5/7            
0,81  
                 
0,19  
                   
3,49  
No  
      
    
 5/8            
0,96  
                 
0,27  
                   
3,38  
No  
      
    
 6/7            
0,97  
                 
0,23  
                   
4,18  
No  
      
    
 6/8            
1,15  
                 
0,32  
                   
4,05  
No  
      
    
 7/8            
1,18  
                 
0,23  
                   
6,02  
No  
      
               
Bsep           
0,00  
          
0,63  
 
Groupings  
           
xi 
 
    
 1/2            
0,37  
                 
0,11  
                   
1,24  
No   1            
0,55  
                                   
0,23  
                              
0,32  
                        
0,95  
         
6,00      
 1/3            
0,30  
                 
0,09  
                   
1,00  
No   2            
1,49  
                                   
0,17  
                              
0,92  
                        
2,41  
         
5,00      
 1/4            
2,04  
                 
0,60  
                   
6,90  
No   3            
1,84  
                                   
0,31  
                              
0,76  
                        
4,48  
         
5,00      
 1/5            
0,46  
                 
0,14  
                   
1,46  
No   4            
0,27  
                                   
0,46  
                              
0,07  
                        
0,99  
         
5,00      
 1/6            
0,21  
                 
0,07  
                   
0,67  
Yes   5            
1,20  
                                   
0,19  
                              
0,76  
                        
1,89  
         
6,00      
 1/7            
0,79  
                 
0,15  
                   
4,11  
No   6            
2,60  
                                   
0,28  
                              
1,33  
                        
5,08  
         
6,00      
 1/8            
0,75  
                 
0,18  
                   
3,11  
No   7            
0,69  
                                   
0,03  
                              
0,36  
                        
1,31  
         
2,00      
 2/3            
0,81  
                 
0,23  
                   
2,88  
No   8            
0,73  
                                   
0,06  
                              
0,51  
                        
1,04  
         
3,00      
 2/4            
5,54  
                 
1,55  
                
19,78  
Yes  
      
    
 2/5            
1,24  
                 
0,37  
                   
4,20  
No  
      
    
 2/6            
0,57  
                 
0,17  
                   
1,94  
No  
      
    
 2/7            
2,16  
                 
0,40  
                
11,62  
No  
      
    
 2/8            
2,04  
                 
0,47  
                   
8,86  
No  
      
    
 3/4            
6,87  
                 
1,92  
                
24,50  
Yes  
      
    
 3/5            
1,54  
                 
0,45  
                   
5,20  
No  
      
    
 3/6            
0,71  
                 
0,21  
                   
2,40  
No  
      
    
 3/7            
2,67  
                 
0,50  
                
14,40  
No  
      
    
 3/8            
2,53  
                 
0,58  
                
10,98  
No  
      
xii 
 
    
 4/5            
0,22  
                 
0,07  
                   
0,76  
Yes  
      
    
 4/6            
0,10  
                 
0,03  
                   
0,35  
Yes  
      
    
 4/7            
0,39  
                 
0,07  
                   
2,10  
No  
      
    
 4/8            
0,37  
                 
0,08  
                   
1,60  
No  
      
    
 5/6            
0,46  
                 
0,14  
                   
1,48  
No  
      
    
 5/7            
1,74  
                 
0,34  
                   
8,99  
No  
      
    
 5/8            
1,64  
                 
0,40  
                   
6,81  
No  
      
    
 6/7            
3,76  
                 
0,73  
                
19,45  
No  
      
    
 6/8            
3,55  
                 
0,86  
                
14,74  
No  
      
    
 7/8            
0,94  
                 
0,15  
                   
5,93  
No  
      
               
Fxr           
0,06  
          
0,35  
 
Groupings  
           
    
 1/2            
1,08  
                 
0,43  
                   
2,71  
No   1            
0,69  
                                   
0,25  
                              
0,37  
                        
1,27  
         
6,00      
 1/3            
0,82  
                 
0,33  
                   
2,06  
No   2            
0,63  
                                   
0,07  
                              
0,52  
                        
0,77  
         
5,00      
 1/4            
0,58  
                 
0,23  
                   
1,44  
No   3            
0,84  
                                   
0,11  
                              
0,62  
                        
1,14  
         
5,00      
 1/5            
0,56  
                 
0,23  
                   
1,35  
No   4            
1,19  
                                   
0,17  
                              
0,74  
                        
1,91  
         
5,00      
 1/6            
0,52  
                 
0,22  
                   
1,26  
No   5            
1,22  
                                   
0,34  
                              
0,54  
                        
2,79  
         
6,00      
 1/7            
0,55  
                 
0,16  
                   
1,89  
No   6            
1,31  
                                   
0,17  
                              
0,87  
                        
1,98  
         
6,00  
xiii 
 
    
 1/8            
0,45  
                 
0,15  
                   
1,31  
No   7            
1,25  
                                   
0,03  
                              
0,74  
                        
2,13  
         
2,00      
 2/3            
0,76  
                 
0,29  
                   
1,98  
No   8            
1,53  
                                   
0,03  
                              
1,28  
                        
1,82  
         
3,00      
 2/4            
0,53  
                 
0,20  
                   
1,39  
No  
      
    
 2/5            
0,52  
                 
0,21  
                   
1,30  
No  
      
    
 2/6            
0,48  
                 
0,19  
                   
1,21  
No  
      
    
 2/7            
0,51  
                 
0,14  
                   
1,79  
No  
      
    
 2/8            
0,41  
                 
0,14  
                   
1,25  
No  
      
    
 3/4            
0,70  
                 
0,27  
                   
1,83  
No  
      
    
 3/5            
0,68  
                 
0,27  
                   
1,71  
No  
      
    
 3/6            
0,64  
                 
0,26  
                   
1,60  
No  
      
    
 3/7            
0,67  
                 
0,19  
                   
2,37  
No  
      
    
 3/8            
0,55  
                 
0,18  
                   
1,65  
No  
      
    
 4/5            
0,97  
                 
0,39  
                   
2,44  
No  
      
    
 4/6            
0,91  
                 
0,36  
                   
2,28  
No  
      
    
 4/7            
0,95  
                 
0,27  
                   
3,38  
No  
      
    
 4/8            
0,78  
                 
0,26  
                   
2,36  
No  
      
    
 5/6            
0,93  
                 
0,39  
                   
2,24  
No  
      
    
 5/7            
0,98  
                 
0,28  
                   
3,36  
No  
      
xiv 
 
    
 5/8            
0,80  
                 
0,27  
                   
2,34  
No  
      
    
 6/7            
1,04  
                 
0,30  
                   
3,60  
No  
      
    
 6/8            
0,86  
                 
0,29  
                   
2,50  
No  
      
    
 7/8            
0,82  
                 
0,21  
                   
3,27  
No  
      
 
Group 1: 1-day control  
Group 2: 1-day p.C-AuNPs  
Group 3: 14 days control  
Group 4: 14 days citrate-AuNPs  
Group 5: 14 days PEG-AuNPs  
Group 6: 14 days p.L-AuNPs  
Group 7: 14 days p.14-AuNPs  
Group 8: 14 days p.C-AuNPs  
 
